4 completed, 2 unknown, 1 recruiting. 2 Not applicable, 2 Phase 2, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow BCC - Basal Cell Carcinoma: new trials by email Literature Review of BCC - Basal Cell Carcinoma trials Research Report on BCC - Basal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery A microsurfaced ADM (acellular dermal matrix) - Wound Healing After MMS Surgery, BCC - Basal Cell Carcinoma | Not applicable | Completed | McGuire Institute | 16 | 2025-08-08 | 2026-04-24 |
| The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes BCC - Basal Cell Carcinoma, BCC | Completed | Vejle Hospital | 210 | 2024-04-04 | 2026-05-26 | |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| L19IL2/L19TNF in Skin Cancer Patients L19IL2/L19TNF - BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 2 | Unknown | Philogen S.p.A. | 70 | 2023-03-09 | 2023-10-06 |
| CellFX Treat & Resect Low-Risk BCC Feasibility Study CellFX System - BCC - Basal Cell Carcinoma, BCC | Not applicable | Completed | Pulse Biosciences, Inc. | 30 | 2021-06-02 | 2023-01-11 |
| Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma Jet injection of ALA, Surgical excision, Illumination - BCC, BCC - Basal Cell Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 16 | 2020-09-09 | 2026-06-18 |
| Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas Nivolumab 10 MG/ML, Ablative fractionated laser - BCC - Basal Cell Carcinoma, Immune Response | Early Phase 1 | Unknown | Bispebjerg Hospital | 30 | 2020-01-27 | 2020-09-30 |
Carcinoma, Basal Cell (7) · Carcinoma, Squamous Cell (3) · Carcinoma, Merkel Cell (2) · Sarcoma, Kaposi (2) · Skin Neoplasms (2) · Adenocarcinoma, Sebaceous (1) · Carcinoma (1) · Carcinoma, Skin Appendage (1) · Eyelid Diseases (1) · Eyelid Neoplasms (1) · Hemangiosarcoma (1) · Hypersensitivity (1) · Margins of Excision (1) · Melanoma (1) · Neoplasm Metastasis (1)
Neoplasms by Histologic Type (7) · Carcinoma (6) · Neoplasms (6) · Neoplasms, Basal Cell (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Squamous Cell (3) · Pathological Conditions, Signs and Symptoms (3) · Adenocarcinoma (2) · Carcinoma, Neuroendocrine (2) · DNA Virus Infections (2) · Head and Neck Neoplasms (2) · Herpesviridae Infections (2) · Infections (2) · Neoplasms by Site (2) · Neoplasms, Connective and Soft Tissue (2)
Infectious Disease Incubation Period (1) · Lighting (1) · Nivolumab (1) · daromun (1) · pembrolizumab (1)
Memorial Sloan Kettering Cancer Center (2) · Bispebjerg Hospital (1) · McGuire Institute (1) · Philogen S.p.A. (1) · Pulse Biosciences, Inc. (1) · Vejle Hospital (1)
United States (4) · Denmark (2) · France (1) · Italy (1) · Spain (1)
Aaron Farberg, MD (1) · Anthony Rossi, MD (1) · Lara Dunn, MD (1) · Mike Drake (1) · Richard A. Nuccitelli, PhD (1)